Literature DB >> 24477666

Improved visual outcome with early treatment in macular edema secondary to retinal vein occlusions: 6-month results of a Korean RVO study.

Young Hee Yoon1, Ha Kyoung Kim, Hee Seong Yoon, Se Woong Kang, June-Gone Kim, Kyu Hyung Park, Young Joon Jo, Joo Yong Lee, Dong Hoon Lee.   

Abstract

PURPOSE: To determine the correlation between the duration of macular edema (ME) and visual outcomes among Korean patients with retinal vein occlusion (RVO).
METHODS: Multicenter, interventional case series. Treatment-naive patients (n = 249) with branch or central RVO (BRVO/CRVO) and ME for <6 months were included. We assessed the correlation between the duration of ME and treatment outcomes including the mean logarithm of the minimum angle of resolution best-corrected visual acuity (logMAR BCVA) improvement, the proportion of patients achieving at least a 3-line gain in BCVA, and the mean reduction in central retinal thickness (CRT) at 6 months.
RESULTS: One hundred and fifty-six patients with BRVO and 93 patients with CRVO were divided into five groups based on the duration of ME (<2, 2-4 weeks, 1-2, 2-3, 3-6 months); the mean baseline BCVA and CRT among the groups did not differ significantly. In BRVO, the mean logarithm of the minimum angle of resolution (logMAR) BCVA improvements in the groups were 0.51, 0.32, 0.17, 0.19, and 0.13, respectively (P = 0.002). The respective percentages of at least 3-line gains were 64, 53, 39, 38, and 21 % (P < 0.001). The BCVA didn't significantly improve in CRVO. The decrease in CRT was not correlated significantly with the duration of ME in either disease.
CONCLUSIONS: Treatment of BRVO as early as 2 weeks after onset of ME enhanced the visual outcome; there was no correlation in the patients with CRVO. This finding supports the current trend favoring early treatment to obtain better visual outcomes in patients with BRVO.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24477666     DOI: 10.1007/s10384-014-0305-9

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  15 in total

1.  Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: Standard Care Versus COrticosteroid for REtinal Vein Occlusion Study report 10.

Authors:  Ingrid U Scott; Paul C VanVeldhuisen; Neal L Oden; Michael S Ip; Barbara A Blodi; Mary Elizabeth Hartnett; Geoff Cohen
Journal:  Ophthalmology       Date:  2011-02       Impact factor: 12.079

2.  Recurrence of macular edema associated with branch retinal vein occlusion after intravitreal bevacizumab.

Authors:  Narihisa Hanada; Hiroyuki Iijima; Yoichi Sakurada; Mitsuhiro Imasawa
Journal:  Jpn J Ophthalmol       Date:  2011-12-20       Impact factor: 2.447

Review 3.  Natural history of central retinal vein occlusion: an evidence-based systematic review.

Authors:  Rachel L McIntosh; Sophie L Rogers; Lyndell Lim; Ning Cheung; Jie Jin Wang; Paul Mitchell; Jonathan W Kowalski; Hiep P Nguyen; Tien Yin Wong
Journal:  Ophthalmology       Date:  2010-06       Impact factor: 12.079

Review 4.  Clinical practice. Retinal-vein occlusion.

Authors:  Tien Y Wong; Ingrid U Scott
Journal:  N Engl J Med       Date:  2010-11-25       Impact factor: 91.245

5.  Prevalence and risk factors of retinal vein occlusion in an Asian population.

Authors:  L L Lim; N Cheung; J J Wang; F M A Islam; P Mitchell; S M Saw; T Aung; T Y Wong
Journal:  Br J Ophthalmol       Date:  2008-08-06       Impact factor: 4.638

Review 6.  Natural history of branch retinal vein occlusion: an evidence-based systematic review.

Authors:  Sophie L Rogers; Rachel L McIntosh; Lyndell Lim; Paul Mitchell; Ning Cheung; Jonathan W Kowalski; Hiep P Nguyen; Jie Jin Wang; Tien Yin Wong
Journal:  Ophthalmology       Date:  2010-06       Impact factor: 12.079

7.  Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.

Authors:  David M Brown; Peter A Campochiaro; Rishi P Singh; Zhengrong Li; Sarah Gray; Namrata Saroj; Amy Chen Rundle; Roman G Rubio; Wendy Yee Murahashi
Journal:  Ophthalmology       Date:  2010-04-09       Impact factor: 12.079

8.  Treatment of macular edema due to branch retinal vein occlusion with single or multiple intravitreal injections of bevacizumab.

Authors:  Tatsuya Yunoki; Akio Miyakoshi; Tomoko Nakamura; Kazuya Fujita; Chiharu Fuchizawa; Atsushi Hayashi
Journal:  Jpn J Ophthalmol       Date:  2012-01-14       Impact factor: 2.447

9.  Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results.

Authors:  Julia A Haller; Francesco Bandello; Rubens Belfort; Mark S Blumenkranz; Mark Gillies; Jeffrey Heier; Anat Loewenstein; Young Hee Yoon; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup; Joanne Li
Journal:  Ophthalmology       Date:  2011-07-20       Impact factor: 12.079

10.  Baseline characteristics and risk factors of retinal vein occlusion: a study by the Korean RVO Study Group.

Authors:  Joo Yong Lee; Young Hee Yoon; Ha Kyoung Kim; Hee Seong Yoon; Se Woong Kang; June-Gone Kim; Kyu Hyung Park; Young Joon Jo
Journal:  J Korean Med Sci       Date:  2013-01-08       Impact factor: 2.153

View more
  5 in total

1.  Predictive factors for recurrence of macular edema after successful intravitreal bevacizumab therapy in branch retinal vein occlusion.

Authors:  Rika Yamada; Akihiro Nishida; Masataka Shimozono; Takanori Kameda; Noriko Miyamoto; Michiko Mandai; Yasuo Kurimoto
Journal:  Jpn J Ophthalmol       Date:  2015-09-03       Impact factor: 2.447

Review 2.  Mechanisms of vision loss in eyes with macular edema associated with retinal vein occlusion.

Authors:  Hiroyuki Iijima
Journal:  Jpn J Ophthalmol       Date:  2018-03-23       Impact factor: 2.447

3.  Dexamethasone Intravitreal Implant for Early Treatment and Retreatment of Macular Edema Related to Branch Retinal Vein Occlusion: The Multicenter COBALT Study.

Authors:  Young Hee Yoon; Jong Woo Kim; Joo Yong Lee; In Taek Kim; Se Woong Kang; Hyeong Gon Yu; Hyoung Jun Koh; Sung Soo Kim; Dong-Jin Chang; Susan Simonyi
Journal:  Ophthalmologica       Date:  2018-04-11       Impact factor: 3.250

4.  Morphological and Functional Outcomes after Intravitreal Dexamethasone Injection for Macular Edema in Patients with Central Vein Occlusion at 48-Week Follow-Up.

Authors:  Cristina Nicula; Dorin Nicula; Anca Rednik; Adriana Bulboaca; Ovidiu Crișan
Journal:  J Ophthalmol       Date:  2020-02-11       Impact factor: 1.909

5.  Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agents for Ocular Vascular Diseases: Clinical Practice Guideline.

Authors:  Homayoun Nikkhah; Saeed Karimi; Hamid Ahmadieh; Mohsen Azarmina; Majid Abrishami; Hossein Ahoor; Yousef Alizadeh; Hasan Behboudi; Narsis Daftarian; Mohammad Hossein Dehghan; Morteza Entezari; Fereydoun Farrahi; Heshmatollah Ghanbari; Khalil Ghasemi Falavarjani; Mohammad Ali Javadi; Reza Karkhaneh; Siamak Moradian; Masoud Reza Manaviat; Morsal Mehryar; Ramin Nourinia; Mohammad Mehdi Parvaresh; Alireza Ramezani; Alireza Ragati Haghi; Mohammad Riazi-Esfahani; Masoud Soheilian; Mohsen Shahsavari; Hossein-Ali Shahriari; Zhale Rajavi; Sare Safi; Armin Shirvani; Saeed Rahmani; Hamideh Sabbaghi; Mojgan Pakbin; Bahareh Kheiri; Hossein Ziaei
Journal:  J Ophthalmic Vis Res       Date:  2018 Apr-Jun
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.